HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a ...

HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop ...

Bio-Path Holdings, Inc. has announced significant progress with its drug BP1001-A, which has shown potential as a treatment for obesity and Type 2 diabetes in recent preclinical studies. The research ...

Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...

HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH),, a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a ...

Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are rocketing higher Friday on heavy trading volume. Here's a look at what's going on: Shares of BPTH are up over 90% on remarkably heavy volume Friday, ...

Bio-Path says the first patient treated with a higher dose in Phase 1/1b study of BP1001-A has shown tumor regression and stable disease. Bio-Path reports its second-quarter financial results last ...

HOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a ...

HOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH),, a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a ...